From: Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
Treatment group
Control
Imatinib
Sunitinib
Regorafenib
Passage
N
Dose
2
Untreated
3
50 mg/kg/BID
n/a
40 mg/kg/QD
4
6
100 mg/kg/BID
30 mg/kg/QD